Angiotech Pharmaceuticals Completes Sale to Investor Syndicate Led by Vivo Capital and ZQ Capital
PALO ALTO, Calif. and VANCOUVER, British Columbia, March 21, 2017 /PRNewswire/ -- Angiotech Pharmaceuticals, a leading medical device company focused on high value medical consumables in the wound closure and ophthalmology sectors, today announced the completion of its sale to a group of investors led by Vivo Capital LLC and ZQ Capital Limited. The investment syndicate also includes GSO Capital Partners LP, China Orient Asset Management (International) Holding Limited, Fung Shing Investments Ltd, ZZ Capital Co., Ltd, ABCI Investment Management Limited, Cathay Venture Inc. and Nan Fung Group. In addition, business development companies managed by affiliates of FS Investments and sub-advised by an affiliate of GSO Capital Partners LP (GSO, a division of The Blackstone Group), ABCI Investment Management Limited, and China Minsheng Banking Corporation Limited, Hong Kong Branch, provided senior secured financing for the transaction. The terms of the transaction were not disclosed.
Surgical Specialties Corporation Announces Approval of Expanded Use for BioSentry™ Track Sealant System in Europe
Braintree, MA – May 20, 2016 – Surgical Specialties Corporation (Surgical Specialties), a leading provider of branded, private label, and OEM medical devices for advanced surgery, wound closure, ophthalmology, and radiology announced today approval for expanded European labeling for its BioSentryTM Track Sealant System. This approval expands the number of patients that can benefit from this technology now that it can be used with a larger 17 gauge biopsy system. This important change allows a significantly greater number of percutaneous transthoracic lung biopsy procedures to be able to use BioSentry™, which is proven to reduce the risk of pneumothorax and subsequent adverse events1.
Surgical Specialties to Acquire Leading German Needle and Suture Manufacturer
Braintree, MA and Jestetten, Germany - January 26, 2016 – Surgical Specialties Corporation (“Surgical Specialties”,”Company”), a leading provider of branded, private label, and OEM medical devices for advanced surgery, wound closure, ophthalmology, and radiology announced today that it has acquired all shares of FSSB Chirurgische Nadein GMBH (FSSB) and affiliated entities. Terms were not disclosed. The acquisition will be immediately accretive to both Surgical Specialties’ sales and adjusted EBITDA.
Surgical Specialties Corporation Announces Medicare Approval of Transitional Pass-Through Reimbursement for BioSentry™ Track Sealant System
Braintree, MA – June 22, 2015 – Surgical Specialties Corporation (Surgical Specialties), a leading provider of branded, private label, and OEM medical devices for advanced surgery, wound closure, ophthalmology, and radiology announced today that the U.S. Centers for Medicare and Medicaid Services (CMS) has approved a transitional pass-through payment for Surgical Specialties’ BioSentryTM Track Sealant System under the Medicare hospital outpatient prospective payment system (OPPS). This important approval removes a potential barrier to patient access to this new medical device, which offers the potential to improve outcomes for patients undergoing a percutaneous transthoracic lung biopsy.
Surgical Specialties Corporation Awarded Three Year Suture Products Agreement with Premier, Inc.
Braintree, MA, March 9, 2015 – Surgical Specialties Corporation, a leading provider of branded, private label , and OEM medical devices for advanced surgical wound closure and ophthalmology, announced today it has been awarded a group purchasing agreement with Premier, Inc. to provide its recently expanded portfolio of suture products to Premier’s extensive network of 3,400 hospitals and 110,000 healthcare providers.
Angiotech announces K. Thomas Bailey departure from board of directors
Angiotech Pharmaceuticals, Inc. announced today that K. Thomas Bailey has stepped down from the company’s board of directors effective immediately.
Surgical Specialties Announces Leadership Team Additions
Surgical Specialties, Inc. announced today two important additions to its executive management team. Daniel (Dan) Sutherby has joined as Chief Financial Officer (CFO) and Brennan Marilla as Chief Commercial Officer (CCO). The company appointedJohn Barr as CEO in October 2014.
Dan, Brennan and John Barr will be based in the Company's recently opened US headquarters in Braintree, MA.
Angiotech appoints John Barr as CEO
Angiotech Pharmaceuticals, Inc. announced today that its Board of Directors has appointed John R. Barr as Chief Executive Officer.